GenomeDx Announces Exclusive Marketing and Distribution Agreement for the Decipher Prostate Cancer Classifier in Israel and the Palestinian Authority
Jun 30, 2015, 08:00 ET
SAN DIEGO, June 30, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that the company signed an exclusive agreement with Medison Pharma Ltd., a leading marketer of innovative healthcare solutions, to distribute the Decipher® Prostate Cancer Classifier in Israel and the Palestinian Authority.
"The partnership with GenomeDx marks an important step in making Decipher available to patients in Israel and the Palestinian Authority. We are committed to expanding access to Decipher for the patients who need it," commented Meir Jakobsohn, Founder & CEO of Medison Pharma.
"The use of advanced tools that can identify the genetic materials found in tumor cells, allows us a better assessment of prostate cancer. It also enables us to adjust the treatment program on an individual basis for each patient according to the results of their own findings. By using this advanced genetic testing, we can reduce the exposure to related therapies in patients after prostatectomy," added Dr. David Margel, Division of Urology at the Davidoff Cancer Center at Rabin Medical Center.
The Decipher® Prostate Cancer Classifier is a highly validated and commercially available genomic test for men with intermediate and high risk prostate cancer. Decipher predicts cancer aggressiveness by looking for a unique genomic signature comprised of a validated series of biomarkers associated with metastatic disease. Adding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors. Clinical studies from leading cancer centers published in over a dozen medical journals demonstrate that Decipher can accurately predict metastatic disease, which men may benefit from radiation therapy following prostate surgery, and can lead to significant cost-savings for healthcare systems. Decipher was developed in partnership with the Mayo Clinic.
Decipher is covered by Medicare and multiple private insurance plans in the US.
Learn more at: www.DecipherTest.com and follow Decipher on Twitter @DecipherTest and on Facebook.
About GenomeDx Biosciences
GenomeDx Biosciences is focused on transforming cancer patient care by putting usable genomic information in the hands of patients and their physicians. GenomeDx is developing and commercializing Decipher®, a highly validated genomic test for predicting metastatic disease in men with prostate cancer. In partnership with leading medical centers, the company has assembled the largest genomic catalogue of prostate cancer tumors in the world, representing billions of data points and more than 20 years of prostate cancer research expertise. Using advanced cloud-based bioinformatics, GenomeDx mines the genomic data to develop proprietary tests that address key clinical questions in cancer patient management. GenomeDx has partnered to share genomic data with leading clinician-scientists worldwide to collaboratively enrich the knowledge and understanding of urologic cancers for the goal of improving global cancer patient care. GenomeDx is based in San Diego, California and Vancouver, British Columbia.
Learn more at www.genomedx.com and follow us on Twitter at @GenomeDx, Facebook, LinkedIn and YouTube.
Medison is Israel's leading marketing group, representing innovative niche healthcare products from companies such as Biogen Idec, Amgen, Shire and Ipsen. Medison has been building and maintaining long-standing relations with HMOs, local medical centers and physicians. Backed by three generations of experience in the healthcare industry since 1937, Medison is uniquely qualified to provide the complete spectrum of integrated services for international companies looking to enter or expand their presence in the Israeli market.
Learn more at: www.medisonpharma.com
Sharon Blum - Goldfinger Communications
E.mail: [email protected]
SOURCE GenomeDx Biosciences
Share this article